Genelux Corporation Releases Q3 2025 Financial Results and Business Updates

November 5, 2025 - 19:07

Genelux Corporation has shared its financial results for the third quarter of 2025, highlighting significant advancements in its lung cancer programs. The company anticipates interim data updates for these programs to be available in the fourth quarter of 2025, showcasing its commitment to developing innovative treatments in the oncology space.

In addition to progress in lung cancer, Genelux is also preparing for the release of topline data from its OnPrime Phase 3 registrational trial focused on ovarian cancer. This crucial data is expected to be disclosed in the second half of 2026, marking a pivotal moment for the company as it aims to establish its presence in the competitive oncology market.

As of September 30, 2025, Genelux reported cash, cash equivalents, short-term investments, and restricted cash totaling $21.0 million. This financial position provides a solid foundation for the company as it advances its clinical programs and continues to seek innovative solutions for cancer treatment.